Tips from Other Journals

SSRI Use in Late Pregnancy Increases Risk of PPHN



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2006 Jun 15;73(12):2227-2230.

Persistent pulmonary hypertension of the newborn (PPHN) is a rare but often fatal condition in which the fetal circulation persists after birth, leading to hypoxemia and respiratory failure. Results of a previous cohort study suggested a possible link between PPHN and maternal selective serotonin reuptake inhibitor (SSRI) use in late pregnancy. Chambers and colleagues conducted a case-control study involving women whose infants developed PPHN to determine whether SSRI use after 20 weeks’ gestation was associated with a higher risk of this condition.

Potential participants were identified from medical record reviews, telephone calls, and referrals at 97 institutions in Boston, Mass.; Philadelphia, Penn.; San Diego, Calif.; and Toronto, Canada. Criteria for PPHN were (1) severe respiratory failure shortly after birth at greater than 34 weeks’ gestation, and (2) evidence of pulmonary hypertension on echocardiography or a difference of more than 5 percent between preductal and post-ductal oxygen saturation. The control group consisted of mothers who delivered healthy newborns at the same hospitals; control participants were matched to patients by delivery dates in a 2:1 ratio.

About seven out of 10 mothers in each group who were invited to participate in the study agreed, making a total of 377 study participants and 836 matched control participants. Mothers who delivered infants with PPHN were more likely than those in the control group to be black (adjusted odds ratio [OR], 2.3; 95% confidence interval [CI], 1.4 to 3.8) or Asian (adjusted OR, 2.2; 95% CI, 1.2 to 3.9) and to have had a pre-pregnancy body mass index greater than 27 kg per m2 (adjusted OR, 2.6; 95% CI, 1.6 to 4.0).

All mothers were interviewed over the telephone within six months after delivery. The interviews were conducted by trained nurses who did not know the study hypothesis and included elicitation of a medication history with specific questions about antidepressant use during pregnancy. To aid recall of medication use, calendars were provided highlighting the dates of the last menstrual period and delivery. Late pregnancy exposure to SSRIs was defined as any use that occurred more than 20 calendar weeks after the first day of the last menstrual period.

Fourteen mothers who delivered infants with PPHN and six control mothers reported using SSRIs after 20 weeks’ gestation. When adjustments were made for potential confounders, multivariate regression analysis demonstrated that mothers who reported using SSRIs in late pregnancy were approximately six times more likely to deliver infants with PPHN than mothers who reported no such use (adjusted OR, 6.1; 95% CI, 2.2 to 16.8). In contrast, no increased risk for PPHN was found with maternal SSRI use before 20 weeks’ gestation or with use of other classes of antidepressants at any time during pregnancy. The results did not change significantly when the analysis was restricted to infants born at 37 weeks’ gestation or later.

The authors conclude that maternal SSRI use after 20 weeks’ gestation is associated with a significantly increased risk of delivering an infant with PPHN. They speculate that higher circulating serotonin levels may predispose newborns to PPHN by stimulating smooth-muscle cell proliferation in the fetal lung and inhibiting nitric oxide synthesis.

Ten to 15 percent of women of reproductive age develop a major depressive disorder. Because the absolute increase in risk for PPHN observed in this study was small (i.e., six to 12 cases per 1,000 births), the authors recommend that physicians incorporate these findings into discussions about the benefits and risks of antidepressant treatment with patients who are pregnant.

Chambers CD, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. February 9, 2006;354:579–87.

editor’s note: Decisions about the use of antidepressant medication ideally should be made before conception. In practice, however, many women continue taking SSRIs for weeks before finding that they are pregnant. This study showed that, regarding the risk of PPHN, the decision of whether to continue SSRI therapy may safely be delayed until 20 weeks’ gestation. At that point, physicians and patients must weigh potential risks to the developing fetus against the risk of recurrent depression. Results from a prospective study1 involving 201 women who were pregnant and had a history of major depressive disorder showed that those who discontinued antidepressants during pregnancy were five times more likely to experience a relapse than those who continued to take their medication. Although there may not be a completely safe choice regarding SSRI use in pregnancy, physicians should make sure that this choice is an informed one.—k.w.l.

REFERENCE

1. Cohen LS, Altschuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295:499–507.

 

Copyright © 2006 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article